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Abstract
Alternatives to conventional hospitalization are needed to increase health systems resilience in the face of COVID-19 
pandemic. Herein, we describe the characteristics and outcomes of 63 patients admitted to a single HaH during the peak of 
COVID-19 in Barcelona. Our results suggest that HaH seems to be a safe and efficacious alternative to conventional hospi-
talization for accurately selected patients with COVID-19.
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Introduction
The COVID-19 pandemic poses a serious challenge to health 
system resilience across the globe [1]. Particularly, hospi-
tal capacity and availability of intensive care unit (ICUs) 
beds and respirators have been identified among the upmost 
relevant factors, which have been critically exceeded in a 
number of countries during the first wave of COVID-19 [1]. 
As many hospitals devoted the bulk of their resources in 
COVID-19, various alternative medical facilities have been 
used to alleviate hospitals and avoid collapse [1].
Hospital at home (HaH) units have proven to be an effec-
tive and safe alternative to conventional hospitalization for 
admission avoidance and early discharge [2]. HaH units 
have been successfully used in a variety of conditions, e.g., 
serious bacterial infections and respiratory viral infections, 
including potentially health system-collapsing situations 
such as the annual peak of seasonal influenza [3–6].
We aimed to describe the characteristics and outcomes of 
patients with COVID-19 transferred from the hospital to a 




Consecutive patients with COVID-19 from March 10 to 
April 5 2020 admitted to the HaH Unit were included. A 
follow-up period of 30 days after discharge from HaH was 
completed for all patients.
Members of the Hospital Clínic 4H Team are listed in the 
Appendix.
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Definitions
The diagnosis of COVID-19 was based on clinical, radio-
logical, and laboratory criteria and microbiological confir-
mation in all patients until March 27, since when disruptions 
in the supply of polymerase-chain reaction tests for SARS-
CoV-2 in Spain resulted in increasing number of suspected 
but not confirmed cases.
Setting
Hospital Clinic is a 750-bed public, tertiary teaching hos-
pital which serves 560,000 people in the metropolitan area 
of Barcelona. The Hospital Clinic’s HaH Unit started pro-
viding hospital-level, specialized, health care at patients’ 
homes in 1996 [7]. The HaH Unit has a maximum capacity 
of 48 patients, with approximately 1200 patients treated each 
year and a mean length of stay of 7 days (standard deviation 
3 days) [8]. Patient care during HaH admission included 
daily medical and nurse visits (in-person, phone calls, and 
video calls), a round the clock call center, usual tests at home 
(blood tests, cultures, EKG, and ultrasound), oral or iv drug 
administration, and transfer to hospital for either further tests 
(e.g., chest X-ray) or planned conventional hospitalization if 
required. In case of rapid deterioration of the clinical status 
objectified during medical or nurse visits or worsening of 
symptoms referred by the patients to the call center, medical 
staff could decide transferring patients via ambulance to a 
reserved area in the hospital, equipped as a semi-intensive 
care unit with two high-level isolation boxes (originally 
set up to visit patients with suspicion of Ebola during the 
2014–2016 outbreak), whereby conducting clinical explora-
tion and complementary tests. From there, patients could be 
admitted to the hospital (either to a COVID-19 ward or ICU) 
or be transferred back to HaH.
Notably, during the study period, a medicalized hotel run 
by HaH staff was being set up and 230 patients visited in 
the ER were transferred there with the same inclusion cri-
teria as HaH. After April 5, almost all HaH resources were 
invested in the medicalized hotel, thereby precluding further 
admissions of COVID-19 patients at home, but instead were 
admitted to the medicalized hotel.
Criteria for transfer to HaH
(1) Caregiver available 24 h at the patients’ home; (2) home 
conditions allowing patient isolation from cohabitants; (3) 
early discharge from hospital ward: more than 6 days since 
the start of symptoms; no fever in the last 24 h; respiratory 
rate < 22 rpm and oxygen saturation > 95% with  FiO2 < 0.35; 
C Reactive protein < 5 mg/dl or descending, normal LDH 
or descending, lymphocytes > 800 cells/mm3 or ascending; 
no radiological progression of pneumonia; (4) admission 
from Emergency room: bilateral pneumonia in patient with-
out high-risk factors (> 65 years old, hypertension, chronic 
obstructive pulmonary disease, cardiovascular disease, dia-
betes, cancer, and immunosuppression); respiratory infection 
without pneumonia, or unilobar pneumonia in patients with 
risk factors.
Ethics
The Ethical Board of the Hospital Clínic evaluated and 
approved the study protocol (HCB.2020.0443). A waiver 
for informed consent was granted due to the state of pan-
demic emergency.
Statistical analysis
Descriptive analysis was performed using SPSS for Win-
dows, version 23.0 (SPSS Inc. Chicago. Illinois. USA).
Results
During the study period, 1783 patients with a diagnosis of 
COVID-19 were visited in the ER. Out of them, 1320 (74%) 
were admitted to the hospital: 63 were transferred to the 
HaH Unit (4.8%), 984 were initially admitted to COVID-19 
wards (74.5%), and 273 were transferred to ICU from the ER 
(20.7%). During the same period, a total of 69 patients were 
evaluated for HaH admission. Six patients were rejected 
(8.7%): 2 patients lived out of the catching area of the HaH 
Unit, 2 patients did not meet the clinical criteria for admis-
sion, 1 patient lived alone, and 1 patient declined the transfer 
to HaH.
The baseline characteristics and features of the 63 patients 
at the moment of admission to HaH are shown in Table 1. 
Median age was 51 years (IQR 40–62) and 54% of patients 
were female. A history of smoking was found in 14.3%, 9.5% 
had diabetes mellitus, and 17.5% had hypertension, of whom 
45.5% either received angiotensin converter enzyme inhibi-
tors or angiotensin receptor blockers. Half of the patients 
(50.8%) were transferred to HaH from hospital wards, while 
a 39.7% were admitted directly from the emergency room. 
Most patients (90.5%) had a positive PCR for SARS-CoV-2 
infection. The total median length of stay was 7 days (IQR 
3.8–10.2), being 1 day in median at the hospital and 6 days 
(IQR 4–8) at HaH.
Fever and cough were the most frequently found clini-
cal manifestations, with a median of 6 days and 10 days of 
symptoms duration prior to hospital and HaH admission, 
respectively (Table2). One patient received oxygen supply at 
HaH. The most common radiological findings were bilateral 
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interstitial infiltrates (34.9%). Four patients (6.3%) were admit-
ted to the ICU before transfer to HaH. Most patients (82.5%) 
received antiviral treatment and 17.5% also received antibacte-
rial agents. Notably, none received systemic glucocorticoids. 
Nineteen percent of patients discontinued at least one antivi-
ral drug due to adverse events or intolerance. Three (4.8%) 
patients required a new hospitalization. No patients died dur-
ing either HaH or follow-up.
Discussion
Our study shows that HaH Units seem to be safe and 
effective in the care of non-severe COVID-19 patients 
and those who presented severely and have overcome the 
acute phase when selection criteria for HaH admission 
are properly applied. Remarkably, the median time from 
symptoms onset to transfer to HaH was 10 days, and the 
25% percentile was 7 days, which is around the timeframe 
described as the one with higher risk of presenting compli-
cations [9]; namely, a notable proportion of patients were 
transferred still in risk of presenting complications and 
yet the outcomes were overall very good, with no patients 
readmitted either to the hospital or the ICU nor dying. 
The criteria applied for considering HaH admission were 
based on previous staff experience in home admissions and 
agreed with the Infectious diseases specialists in light of 
the growing knowledge and experience in COVID-19 at 
the time. Retrospectively, these criteria might have been 
conservative, although larger studies to validate a HaH 
admission score for COVID-19 should be proposed.
Although safety was overall good when considering 
clinical outcomes and readmissions, a more nuanced 
approach is required to address drug-related side effects, 
which led to a 19% discontinuation rate. This points to 
very aggressive local treatment guidelines indicating by 
that time the largely not evidence-based use of drugs in 
a low-risk population in which the “do not harm” motto 
should prevail.
Thorough cost-effectiveness studies are needed to com-
prehensively evaluate the sustainability and economic 
impact of alternatives to conventional hospitalization dur-
ing the COVID-19 pandemic; however, our study interest-
ingly showed a short median length of admission at the 
hospital before transfer and also an overall short admission 
including the HaH stay. Studying alternatives to conven-
tional hospitalization during the COVID-19 pandemics 
is of utmost importance not only due to the relationship 
between the healthcare systems capacity, including short-
ages on medications, respirators, and protective equipment 
with overall outcomes during the peak in each country 
[1, 9, 10], but also because the COVID-19 entails a large 
economic burden that has still not yet at its fullness. HaH 
units are integrated, flexible, and easy scalable platforms 
that can be cost-efficiently adapted to high demand situa-
tions such as the COVID-19 pandemic.
Our study is constraint by several limitations. First, the 
sample size is small and the analysis is based on limited 
experience of patients collected during a short period of 
time as previously simultaneously HaH staff was respon-
sible for adapting a Hotel for COVID-19 patients with 
the same admission criteria as in HaH. Second, the small 
Table 1  Baseline characteristics and transfer data of COVID-19 
patients admitted to the Hospital at Home the study period (N = 63)
ACEi Angyotensin converter enzyme inhibitors, ARB Angyotensin 
II receptor blockers, CA calcium antagonists, ED emergency depart-
ment, HaH hospital at home, PCR polymerase-chain reaction
Baseline characteristics
 Age, years (median, IQR) 51 (40–62)





 Dyslipidaemia, n (%) 10 (15.9)
 Diabetes mellitus, n (%) 6 (9.5)
 Hypertension, n (%) 11 (17.5)






 Chronic lung disease, n (%) 4 (6.3)
 Ischemic heart disease, n (%) 3 (4.8)
 Moderate–severe chronic renal failure, n (%) 2 (3.2)
 Moderate–severe chronic liver disease, n (%) 1 (1.6)
 Neoplasm, n (%) 4 (6.3)
Data at Hospital at home admission




 Number of live-in partners at home, median (IQR) 1 (1–2)
 Nasopharyngeal swab for SARS-CoV-2, n (%) 60 (95.2)
  Days after admission, median (IQR) 0 (−0.5 to 1)
  Days after symptoms onset, median (IQR) 6 (3–8)
  Positive PCR, n (%) 57 (90.5)
 Total length of stay in days, median (IQR) 7 (3.8–10.2)
  Length of stay at HAH days, median (IQR) 6 (4–8)
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Table 2  Clinical and therapeutic 
features and outcomes of 
COVID-19 patients admitted to 










 Length of symptoms until transfer in days, median (IQR) 10 (7–16)
 Use of oxygen supply, n (%) 1 (1.6)
Blood test parameters at admission
 C Reactive Protein, median mg/dL (IQR) 2.6 (1.0–4.9)
 Procalcitonin, median ng/mL (IQR) 0.03 (0.03–0.05)
 Lactate dehydrogenase, median U/L (IQR) 249 (191.5–299.8)
 Lymphocytes per  106/L, median (IQR) 1100 (900–1400)
 D-dimer, median ng/mL (IQR) 400 (300–575)
 Ferritin, median ng/mL (IQR) 262 (110–526)
 AST, median U/L (IQR) 31.5 (24.8–44)
 ALT, median U/L (IQR) 28 (22–53)
 Bilirubin, median mg/dL (IQR) 0.5 (0.4–0.6)
 Alkaline phosphatase, median U/L (IQR) 66.5 (51–82.8)
 Gamma-glutamyl transpeptidase, median U/L (IQR) 30 (20–55)
 Creatinine, median mg/dL (IQR) 0.79 (0.68–0.94)
 Prothrombin time, % (IQR) 90.8 (83.9–99.2)
Initial radiological findings
 No initial chest X-ray performed, n (%) 8 (12.7)
 Radiological pattern, n (%)
 Normal chest X-ray 6 (9.5)
 Unilateral interstitial infiltrates 19 (19.2)
 Unilateral spotted interstitial infiltrates 2 (3.2)
 Bilateral interstitial infiltrates 22 (34.9)
 Other 6 (9.5)
Complications, n (%)








 Received treatment for COVID-19, n (%) 52 (82.5)
 Lopinavir/ritonavir, n (%) 39 (61.9)
 Median days (IQR) 7 (3.2–10)
 Hydroxychloroquine, n (%) 51 (81.0)
 Median days (IQR) 5 (5–7)
 Azithromycin, n (%) 38 (60.3)
 Median days (IQR) 5 (5–5)
 Remdesivir, n (%) 1 (1.6)
 Tocilizumab 5 (7.9)
 Other antiviral agents, n (%) 5 (7.9)
 Received antimicrobials to cover a potential bacterial infection, n (%) 11 (17.5)
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number of events prevented us to analyze risk factors of 
readmission, new consultations to the hospital, or death. 
Third, our HaH unit has some particularities (strong infra-
structural assets and expertise) that might at some extent 
hamper reproducibility. Fourth, due to the lack of evidence 
available at during the study period, the clinical criteria 
for indicating HaH transfer either from the hospital wards 
or the ED included in the local protocols of our institution 
was largely not based on evidence coming from studies on 
COVID-19 (e.g., risk scores for the progression of disease 
or ICU admission in COVID-19 patients were still not 
available). And finally, during the study period and before 
hospitals risked collapsing, the general trend in Catalonia 
and in our institution, in particular, was to admit almost 
all COVID-19 patients either to the HaH or the hospital 
unless they were asymptomatic, without chest infiltrates, 
and symptoms had started more than 2 weeks earlier. In 
spite of these shortcomings, we believe that our prelim-
inary findings might be of great use to guide potential 
decentralization pathways of COVID-19 care from hospi-
tals, therefore improving efficiency and patients’ comfort, 
and reducing hospital overload during COVID-19 peaks, 
as well as costs and nosocomial infections, among other.
In conclusion, hospital at home units seems to be safe 
and efficacious for providing care to selected patients 
with COVID-19 and, therefore, can be used as a measure 
to reduce the healthcare pressure at hospitals. Patients’ 
selection based on severity or potential development of 
complications seems crucial to optimize the outcomes; 
however, further studies investigating the optimal criteria 
for admission of COVID-19 patients in these outpatient 
facilities are warranted.
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Appendix
Members of the H4H team
Andrea Arenas, Pol Maymó, Eugenia Butori, Carmen 
Aranda, Marta Sala, Ana Fernández, Cristina Escobar, Laura 
Moreno, Adolfo Suarez, Susana Cano, Maribel Avalos, Anna 
Carbonell, Regina Garcia, Nuria Subirana, Jose Vicente 
Picón, Magali Rodriguez, Maria Martinez, Alba Martinez, 
Elisabeth Rosero, Maria Asenjo (Hospital at Home Unit, 
Medical and Nurse Direction); Almudena Sánchez, Aida 
Alejaldre, Sara Llufriu, Daniela Lopera, Patricia Buendia, 
Guadalupe Fernandez, Maria Navarro (Neurology Ser-
vice, Institut Clinic de Neurociències); Miguel Ángel Tor-
rente, Andrea Rivero, Marta Cervera, Desiré Vigo Conde, 
Alberto Fernández (Hematology Service, Institut Clinic 
d’Hematologia i Oncologia); Francis Espósito (Oncology 
Service, Institut Clinic d’Hematologia i Oncologia); Dan-
iela Barreto (Radiation Oncology Service, Institut Clinic 
d’Hematologia I Oncologia); Agustí Toll, Daniel Morgado 
Josep Riera, Constanza Riquelme, Andrea Combalía (Der-
matology Service, Institut de Medicina i Dermatologia); 
Josep M Nicolás, Alfons López-Soto, Álex Soriano, Ramón 
Estruch, Joaquim Fernàndez-Solà, Marta Farré (Internal 
Medicine Service, Institut Clínic de Medicina i Dermatolo-
gia); Elena Guillén, Ana Santamaria, Lidia Gomez, Mònica 
Sorroche (Nephrology Service, Institut Clinic de Nefrolo-
gia i Urologia); Monica Peradejordi, Alberto Tello, Juan M 
López, Antonio Alcaraz (Urology Service, Institut Clinic 
de Nefrologia i Urologia); Roberto Gumucio, Belén Massó 
ALT aspartate aminotransferase, ALT alanine aminotransferase
Table 2  (continued)
 Received glucocorticoids, n (%) 0
Outcomes
 Treatment discontinuation due to adverse events, n (%) 12 (19)
 Readmission to hospital during HaH, n (%) 1 (1.6)
  Days after transfer to HaH, median (IQR) 5 (−)
 New consultation after HaH discharge, n (%) 3 (4.8)
  Days after discharge, mean (IQR) 4 (2–6)
 Readmission to hospital after HaH discharge, n (%) 2 (3.2)
  Days after discharge, mean (IQR) 3.5 (1–6)
Death, n (%) 0
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(Reumathology Service, Institut Clinic d’Especialitats 
Médico-Quirùrgiques), Carolina Montoya (Traumatology 
and Orthopedics Service, Institut Clinic d’Especialitats 
Mèdico-Quirúrgiques), Josep Miranda, Elena Salas, Carlos 
Garcia, (AGC); Gemma Martinez, Antoni Castells (Nurs-
ing and Medical Direction); Laura Perelló, Raquel Crespo, 
Ariadna Patricia Mejía (CDI); Roser Cadena, Maria Gal-
isteo (DIR.Qualitat); Natalia Charines, Mª Carmen Hernán-
dez, Julia Prieto, Laia Sarto, Marta Jimenez, Maria Jesús 
Sánchez (ICGON); Immaculada Sebastián, Silvia Vidorreta 
(CDB); Anna Campreciós, Olga Hernando, Carmen Tares 
(A.QUIR); Ana Mancebo (ICMDM); Gemma Mercade 
(ICOF); Darwin Barboza, Emilia Abad (ICR); Anna Planell 
(CDB); Ana Labarta, Jaume Gas, Andrea Ocaña, and Eva 
Martinez (CAPSBE); all from Hospital Clínic de Barcelona, 
Barcelona, Spain.
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